The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Dr. Maurie Markman on Developing Research Into Checkpoint Inhibitors in Ovarian Cancer

Maurie Markman, MD
Published Online:2:31 PM, Mon December 28, 2015

Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, discusses characterizing tumor types in ovarian cancer and treating the malignancy with checkpoint inhibitors. Markman says only recently have papers been published on checkpoint inhibitors in the treatment of ovarian cancers, marking just how far behind research is on the topic compared to other cancers.

Markman adds despite being behind on research, objective response rates to these treatments in patients with ovarian cancer have been between 10% and 15%. Though these treatments may not be able to shrink ovarian cancer tumors, Markman says a good start would be for checkpoint inhibitors to stop their growth.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.